Published in Vaccine Weekly, April 1st, 1996
Simple monomeric proteins are by themselves only poorly immunogenic. But the creation of particulate, polyvalent antigens permits the elicitation of immune responses without the risks posed by live attenuated pathogens.
In a presentation to the Cambridge Healthtech Institute's Vaccines: New Technologies and Applications conference, held March 18-20, 1996, in McLean, Virginia, researcher Guy Layton of British Biotech Pharmaceuticals Ltd., Oxford, England, summarized the advantages of particulate antigen...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly